Beacon Biosignals: $1.2B valuation, IPO Readiness 57, series_d. AI-powered neuroscience platform analyzing brain signals for clinical and pharma applications. Track live on The IPO Stack.
AI-powered neuroscience platform analyzing brain signals for clinical and pharma applications
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Beacon Biosignals IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Beacon Biosignals has not announced a specific IPO date as of 2026. Track TechStackIPO for the latest funding milestones and IPO signals. Subscribe to The IPO Stack newsletter for weekly updates.
Beacon Biosignals is valued at $1.2B as of the most recent funding round. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Beacon Biosignals shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Beacon Biosignals scores 57/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Beacon Biosignals has raised $282M in total venture capital and private equity funding, with backing from JSL Health, Palo Santo.
Beacon Biosignals's notable investors include JSL Health, Palo Santo. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Beacon Biosignals is a AI / Neuroscience / Healthcare company. AI-powered neuroscience platform analyzing brain signals for clinical and pharma applications.